The effect of cisapride, a new gastrointestinal prokinetic drug, on oesophageal motility and acid reflux was studied in 14 children with gastro-oesophageal reflux disease, receiving either placebo or cisapride 0-15 mg/kg intravenously. Cisapride significantly (p<001) increased the lower oesophageal sphincter pressure (+124%), the amplitude (+84%) and duration (+24%) of oesophageal peristaltic waves, whereas the placebo treatment did not produce any changes. Subsequently, all 14 children underwent 24 hour oesophageal pHmonitoring before and after four weeks of treatment with oral cisapride 0-2 mg/kg tid given in addition to postural therapy and thickened feedings. The 24 hour intraoesophageal pH recordings and symptomatic scores were compared with those of 10 control patients treated only by postural therapy and thickened feedings. When compared with baseline pH data, cisapride significantly reduced the oesophageal acid exposure time, the mean duration of each reflux episode, the duration of the longest reflux episode and the number of long lasting reflux episodes; the number of reflux episodes was not influenced. The effect of cisapride was marked and consistent during fasting and sleep periods. Oesophageal acid exposure was reduced more significantly in patients given cisapride (-61%) than in controls (-
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The effect of cisapride, a new gastrointestinal prokinetic drug, on oesophageal motility and acid reflux was studied in 14 children with gastro-oesophageal reflux disease, receiving either placebo or cisapride 0-15 mg/kg intravenously. Cisapride significantly (p<001) increased the lower oesophageal sphincter pressure (+124%), the amplitude (+84%) and duration (+24%) of oesophageal peristaltic waves, whereas the placebo treatment did not produce any changes. Subsequently, all 14 children underwent 24 hour oesophageal pHmonitoring before and after four weeks of treatment with oral cisapride 0-2 mg/kg tid given in addition to postural therapy and thickened feedings. The 24 hour intraoesophageal pH recordings and symptomatic scores were compared with those of 10 control patients treated only by postural therapy and thickened feedings. When compared with baseline pH data, cisapride significantly reduced the oesophageal acid exposure time, the mean duration of each reflux episode, the duration of the longest reflux episode and the number of long lasting reflux episodes; the number of reflux episodes was not influenced. The effect of cisapride was marked and consistent during fasting and sleep periods. Oesophageal acid exposure was reduced more significantly in patients given cisapride (-61%) than in controls (-24%; p<0-001). Symptom improvement was greater after four weeks of cisapride treatment (score reduction: 61%) than after postural .ad dietary therapy alone (score reduction: 42%; p<001). No adverse effects occurred. These findings suggest that cisapride is a valuable drug in the management of gastro-oesophageal reflux disease in children.
Gastro-oesophageal reflux (GOR) disease is one of the commoner problems encountered by paediatricians, potentially causing serious morbidity and even mortality. ' 
Methods

SUBJECTS
Fourteen patients (group A) aged 15-7 (11 5) months (mean (SD)) (range: 2-38 months) were referred to our division over a one year period with symptoms and signs suggestive of GOR (Table I) .
Informed consent was obtained from the parents of all infants and the study was approved by the Ethical Committee of our Faculty.
Oesophagitis was documented in seven cases by endoscopy and biopsy. In none of the patients was there any evidence of neurologic, metabolic, infectious, or alimentary disorders. Oesophageal manometry and continuous recording of distal oesophageal pH were obtained in all subjects. Manometry was performed by three water filled polyvinyl tubes (id 0-6 mm) assembled with tetrahydrofuran and set up to measure intraluminal pressure at three points, 2-5 cm apart, through distal side openings oriented at 1200. The recording tubes were infused with distilled water by a low compliance pneumohydraulic system (Arndorfer Med Spec) at a constant rate for at least 20 seconds, or as the occurrence of an additional decrease of at least 1I0 pH unit during periods of pH less than 4. All patients tolerated the examination well. Children were given the usual daily feeds in a volume determined by their appetite. Oesophageal pH was recorded on a modified computer monitor (Proxima 'ligth', Sensormedics, Italy) and analysed on an IBM personal computer. The following variables were analysed: (1) percentage of time the oesophageal pH was less than 4 (% GOR); (2) number of GOR episodes; (3) number of GOR episodes lasting >5 minutes; (4) mean duration of reflux (total time pH<4 divided by the number of GOR episodes); (5) duration of longest episode of reflux (min) .
Analysis of the pH tracings was geared to the entire recording period, the waking and sleep periods, which, together, constitute the entire period, and the postprandial (less than two hours after feeding) and fasting periods (more than two hours after feeding) which, together, also constitute the entire period. Endoscopy (1-09); p<0-01; change +24%). Persistalsis duration was unchanged following placebo infusion (Fig 3) . There was no significant change in peristalsis velocity either after cisapride (basal value: 2-63 (1-37) cm/s) or placebo (basal value: 2-57 (1-47) cm/s) throughout the period of recording.
The results of both basal and four week pH probe studies performed in the 14 patients treated with oral cisapride appear in Table III . There was a significant improvement of the intra-oesophageal pH variables for the total recording period, the fasting period and the waking and sleep periods, whereas only % GOR and duration of the longest reflux episode significantly decreased in the postprandial period. The change in number of GOR episodes did not reach significance in any of the various temporal phases of the pH analysis.
The clinical assessment revealed a significant improvement of the symptom score (baseline: [16] [17] [18] [19] [20] [21] (3 72 1 9) 17-3 (9 2) Post-trial 9 5(3 2)t 13-9(11-8)t 2-3(2-6)t 4-0(3-5)t 13-2(13-3)t After 2 post-prandial hours p<0-001). No adverse effects were observed or reported.
No statistically significant differences were found for the initial symptom score (15-70 (2 26)) and for the initial pH values (Table IV) between the 10 patients who were only treated with postural and dietary measures (group B) and the 14 children treated with oral cisapride (group A). At four weeks, the symptom score in group B was 9 30 (3-74) (p<001 v baseline value) -that is, a reduction of 42 (16)%. The percentage decrease in score was significantly more marked (p<0-01) in group A, however (61 (14)%). Furthermore, the three patients in group B with respiratory symptoms (one with bronchitis, two with choking and/or nocturnal cough) still had respiratory complaints such as chronic cough and upper airway congestion at the four week clinical assessment. The prolonged oesophageal pH-monitoring in group B (Table IV) showed at four weeks a significant reduction of total and fasting oesophageal acid exposure (% GOR), of the number of GOR episodes of more than five minutes over 24 hours and of the duration of the longest episode of reflux in the waking period, in comparison with the baseline. At the four week pH-monitoring, however, the total time of oesophageal exposure to acid was normal (<2 SD from the mean value in a control population)9 in only one patient in group B, whereas eight of the 14 patients receiving chronic cisapride showed a normal value for total oesophageal acid exposure. The percentage improvement in 24-hour acid exposure time at four weeks was 61 (19)% in group A and 24 (25)% in group B (p<O-OOl).
At the end of the six week cisapride treatment after the initial four weeks, the clinical score in group B was 2-60 (2-01) (p<0-01 v baseline score).
Discussion
Considerable evidence has recently emerged suggesting that GOR patients have oesophageal and gastric motor abnormalities that contribute to the pathogenesis of GOR disease.' Therefore, treatment of GOR disease by motility modulating drugs would be expected to be a rational measure.
A variety of promotility drugs, such as bethanechol (a muscarinic agonist), metoclopramide (a dopamine antagonist with cholinomimetic agonist effects) and domperidone (a benzimidazole derivative with peripheral dopamine antagonist properties) have been used in the treatment of GOR in children as well as in adults.'0"I There are conflicting reports on the effects of these drugs, both on GOR symptoms and mucosal inflammation.'2-7 It should also be emphasised that these drugs are not devoid of considerable side effects related either to dopamine antagonism or to non-specific cholinergic activity. 1X-20 Our manometric data represent the first controlled study in paediatrics to have evaluated the acute effect of cisapride on parameters of oesophageal motility. Cisapride, which is thought to act selectively on the gut by increased release of acetylcholine from intramural cholinergic nerves, produces a significant increase in LOS basal strength as well as in peristaltic amplitude and duration. These results are consistent with previous studies showing that cholinergic innervation is involved in the regulation of oesophageal motility. 2 The pH analysis revealed that patients who underwent only positional and dietary therapy showed a decrease in total oesophageal acid exposure (% GOR) four weeks after beginning treatment. This improvement, however, and in particular, the normalisation were significantly less marked than in the cisapride group. It should be also emphasised that administration of cisapride induced a significant decrease in acid exposure during sleep, whereas the latter remained high in patients treated only by positional therapy: indeed, the three patients in the latter group who presented with symptoms involving the respiratory tract were still symptomatic at four week assessment. Even though, as compared with baseline, the four week clinical score was decreased in patients who did not receive any drugs, the score improvement was much more salient in patients treated by cisapride.
Our data indicate that cisapride can be an effective and well tolerated drug for the treatment of symptomatic GOR in paediatrics. Preliminary clinical trials in children have shown that cisapride has significant potential in decreasing symptoms and promoting healing of moderate oesophagitis.'32 33 For future therapeutic trials, it would be desirable to include children with severe oesophagitis. 
